British biotech ViaNautis raises a $25M Series A round to accelerate the development of products using the polyNaut® platform

ViaNautis is on a mission to exploit the unique capabilities of the revolutionary polyNaut® technology. Here are details of ViaNautis‘ latest funding round :

🚀 Launch


🏭 Industry



Francesca Crawford (CEO)

💸 Funding & Investors

INVESTMENT (Novembre 2023)$25 million (Series A)
INVESTORS (Novembre 2023)led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors including Origin Capital, Meltwind and O2H.

🎯 Funding purpose

Accelerate the development of products using the polyNaut® platform, expand the scientific and management teams and establish laboratory facilities.

🌐 Country HQ

UK (Cambridge)

Leave a Reply

Your email address will not be published.